Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Although sarcopenia is closely linked to dementia, particularly Alzheimer disease (AD), there are few studies examining the prevalence and associated factors of sarcopenia in subjects with AD. This study aimed to investigate the prevalence of sarcopenia, factors associated with sarcopenia in elderly subjects with AD, and differences in muscle functions of the upper and lower extremities and gait speed at various stages of AD. We evaluated handgrip and knee extension strength, muscle mass, and gait speed in 285 elderly outpatients with probable AD (mean age 82. 0 ± 5.3 years), including early AD ( n = 82), mild AD ( n = 90), and moderate AD ( n = 113), and 67 elderly outpatients with normal cognition (NC) (mean age 81.1 ± 4.7 years).

What this study adds

Evidence grade: Low

The record lists 82 participants. This study investigated the prevalence of sarcopenia and differences in muscle function and gait speed at various stages of Alzheimer's disease in 285 elderly outpatients. It is about muscle function and does not test any treatment, so it says nothing about curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ogawa, Y., Kaneko, Y., Sato, T., Shimizu, S., Kanetaka, H., & Hanyu, H. (2018). Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease. Frontiers in neurology. https://doi.org/10.3389/fneur.2018.00710

Vancouver

Ogawa Y, Kaneko Y, Sato T, Shimizu S, Kanetaka H, Hanyu H. Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease. Frontiers in neurology. 2018. doi:10.3389/fneur.2018.00710. PMID: 30210435.

BibTeX

@article{ogawa2018-30210435,
  author  = {Ogawa, Y. and Kaneko, Y. and Sato, T. and Shimizu, S. and Kanetaka, H. and Hanyu, H.},
  title   = {{Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease}},
  journal = {Frontiers in neurology},
  year    = {2018},
  doi     = {10.3389/fneur.2018.00710},
  pmid    = {30210435},
  url     = {https://doi.org/10.3389/fneur.2018.00710}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study investigated the prevalence of sarcopenia and differences in muscle function and gait speed at various stages of Alzheimer's disease in 285 elderly outpatients. It is about muscle function and does not test any treatment, so it says nothing about curing or preventing Alzheimer's disease.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in neurology)
Journal's citation record 2 / 4 Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 1 / 4 82 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 169 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 16.9 citations a year over 10 year(s) since 2018
Impact for its field and year 3 / 6 Cited 7.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 3 / 4 Cited 55 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Haruo Hanyu: h-index 44 (OpenAlex, whole career)
Institution's track record 0 / 3 Tokyo Medical University: institution h-index 342 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30210435)
Free to read 2 / 2 Free to read
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Cognitive tests and assessment from nearby years

Also in Cognitive tests and assessment

92 studies in the library are filed under Cognitive tests and assessment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Cognitive tests and assessment hub.

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →